Serving the greater Los Angeles Community for over 30 years Focusing on the diseases that affect you. Over 30 years of experience conducting Phase I-IV clinical trials

FOCUSING ON THE DISEASES THAT AFFECT OUR COMMUNITIES

Diabetes and Obesity

Millions of adults in the US are affected by type 2 diabetes and/or obesity. View our current studies in these areas.

View Studies

Hypertension & High Cholesterol

Hypertension & high cholesterol are often linked. Are you affected by any of these? Click to see our current studies.

View Studies

Liver Disease

Know your liver’s health! We provide liver ultrasounds as part of our liver studies’ prescreen process.

View Studies

Women’s Health & General Medicine

From endomitosis to PCOS, we provide a variety of options for women’s health clinical trials.

View Studies

Central Nervous System

Our CNS studies vary in the areas of Psychiatry and Neurology.

View Studies

COVID-19 Vaccine

COVID-19 Vaccines & Treatments: Be part of the COVID-19 solution!

View Studies

A Note from the CEO

Welcome to NRI!
I hope that as you navigate our website, you will learn more about our company and the qualities that make it so special. At NRI, we strive for excellence in clinical trials including placing our patients’ best interests and safety first. For more than 30 years, we take pride in being part of the solution by advancing live-saving medicines for the diseases that affect our communities. Whether you are a Sponsor, Contract Research Organization, or possible study participant, we welcome you with open arms and look forward to serving you with compassion and high quality.

–Samira Moran

Interested in volunteering for a clinical trial?

Join the NRI team in the advancement of life saving medicines and care.
Call (213)-483-1800 or click below:

Find Out More

LATEST NEWS

Read More
January 4, 2021 – Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin- Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

Please CLICK HERE to read the … Read More

Read More
November 24, 2020 – Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2

Please CLICK HERE to read the … Read More

Read More
December 15, 2020 – Diabetes, Liver Disease Epidemics Call for Early Detection, Monitoring, Lifestyle Changes

The inextricable, well-documented link between the twin epidemics of nonalcoholic … Read More

Read More
December 15, 2020 – National Research Institute Announces Enrollment of Volunteers for a Phase 3 Study of NVX-CoV2373 Vaccine Candidate Against COVID-19

Tuesday, December 15, 2020, 8:00 AM PST
LOS ANGELES – … Read More

Read More
October 16, 2020 – NRI is Excited to Share these Clinically Relevant Results for the Efficacy and Safety of Exenatide plus Dapagliflozin for Patients with Uncontrolled Type 2 Diabetes Taking Metformin

NRI is excited to share these clinically relevant results for … Read More

Read More
September 22, 2020 – More Exciting News to Share from Dr. Frias and the NRI Team!

Take a look at our latest publication. We are honored … Read More

NRI CLINICS ARE CURRENTLY OPEN!
COVID-19 Information
X